Effect of omega-3 PUFA on Huntington's disease pathways (WP5470)
Homo sapiens
These are pathways connected to both the wildtype huntingtin (HTT) gene and the mutated huntingtin (mHTT) gene related to neurodegeneration, apoptosis, cholesterol and GABA synthesis and its relation to Omega-3 polyunsaturated fatty acids. The ERK pathway is implicated in Huntington’s disease. The ligands BDNF, EGF, and Glu bind to their respective receptors (TrkB, EGFR, mGluR) and start a signal transduction pathway starting with RAS and RAF1, which leads to the stimulation of MEK then ERK. ERK promotes function of MSK1 (a downstream kinase), ElK1 and CREB (transcription factors), and caspases 3/7 (apoptotic molecules). These downstream targets are implicated in producing the effects of Huntington’s disease at the cellular level. This pathway is based on Figure 1 from Bodai et al. Proteins on this pathway have targeted assays available via the CPTAC Assay Portal
For a description of pathway objects, see the WikiPathways Legend.
Authors
KimberleyBijl , Eric Weitz , Egon Willighagen , and Daniela DiglesActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
Rare DiseasesAnnotations
Cell Type Ontology
oligodendrocyte neuron astrocyteDisease Ontology
Huntington's diseasePathway Ontology
disease pathway Huntington's disease pathway signaling pathwayReferences
- Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Nat Genet. 2003 Sep;35(1):76–83. PubMed Europe PMC Scholia
- Huntingtin associated protein 1 and its functions. Wu LL yan, Zhou XF. Cell Adh Migr. 2009;3(1):71–6. PubMed Europe PMC Scholia
- A novel target for Huntington’s disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington’s disease and its upregulation ameliorates pathology. Bodai L, Marsh JL. Bioessays. 2012 Feb;34(2):142–8. PubMed Europe PMC Scholia
- Defining the role of the Bcl-2 family proteins in Huntington’s disease. Sassone J, Maraschi A, Sassone F, Silani V, Ciammola A. Cell Death Dis. 2013 Aug 15;4(8):e772. PubMed Europe PMC Scholia
- Study of cholesterol metabolism in Huntington’s disease. Leoni V, Caccia C. Biochem Biophys Res Commun. 2014 Apr 11;446(3):697–701. PubMed Europe PMC Scholia
- Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Dyall SC. Front Aging Neurosci. 2015 Apr 21;7:52. PubMed Europe PMC Scholia
- Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP. Hong Y, Zhao T, Li XJ, Li S. J Neurosci. 2016 Aug 24;36(34):8790–801. PubMed Europe PMC Scholia
- Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration? Shirooie S, Nabavi SF, Dehpour AR, Belwal T, Habtemariam S, Argüelles S, et al. Pharmacol Res. 2018 Sep;135:37–48. PubMed Europe PMC Scholia
- Insights into GABAAergic system alteration in Huntington’s disease. Hsu YT, Chang YG, Chern Y. Open Biol. 2018 Dec 5;8(12):180165. PubMed Europe PMC Scholia
- Molecular Pathophysiological Mechanisms in Huntington’s Disease. Jurcau A. Biomedicines. 2022 Jun 17;10(6):1432. PubMed Europe PMC Scholia